Vector for gene therapy and method of quantifying target protein in mammal or cultured cells with the administration of the vector for gene therapy
OwnerHaruo Hanawainventor
Life of this patent
Estimating the term…
Abstract
Disclosed is a vector for gene therapy, by which the blood level of a desired protein can be monitored at high sensitivity when a gene therapy is conducted, wherein the label peptide does not have a physiological activity and has no immunogenicity in many mammals. The vector for gene therapy comprises a nucleic acid coding for a fusion protein of glucagon C-terminal side 19-29 amino acid peptide region and a desired protein region which should be produced in the body, which nucleic acid is incorporated into an expression vector for mammalian cells.
Claims16
A vector for gene therapy comprising an expression vector for mammalian cells and a nucleic acid coding for a fusion protein of glucagon C-terminal side 19-29 amino acid peptide region and a desired protein region which should be produced in the body, which vector can produce said fusion protein in the mammalian cells.
A label for labeling a desired protein produced by expression of an externally administered expression vector in the body of a mammal or in cultured mammalian cells, consisting essentially of glucagon C-terminal side 19-29 amino acid peptide.
A label for labeling a desired protein produced by expression of an externally administered expression vector in the body of a mammal, consisting essentially of glucagon C-terminal side 19-29 amino acid peptide.
A method for labeling a protein produced in the body or in cultured cells, comprising labeling a desired protein produced in the body or in cultured cells with glucagon C-terminal side 19-29 amino acid peptide by expressing said desired protein produced by expression of an externally administered expression vector in the body of a mammal or in cultured mammalian cells, as a fusion protein with said glucagon C-terminal side 19-29 amino acid peptide as a label.
Use of glucagon C-terminal side 19-29 amino acid peptide as a label for a desired protein produced by expression of an externally administered expression vector in the body of a mammal or in cultured mammalian cells.
Use of glucagon C-terminal side 19-29 amino acid peptide as a label for a desired protein produced by expression of an externally administered expression vector in the body of a mammal.
Dependencies are inferred from the claim text.